文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT在初次活检前检测前列腺癌的诊断效能:与癌症预测列线图的比较

Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-01-11

该回顾性研究纳入58例疑似前列腺癌且tPSA为0.4-50 ng/ml的患者,评估68Ga-PSMA PET/CT检测前列腺癌的诊断效能并与ERSPC和PCPT列线图比较。结果显示68Ga-PSMA PET/CT的AUC为0.867,高于ERSPC-RC3的0.855和PCPT-RC的0.770,且在15-90%阈值概率内净获益最大,可减少不必要的活检。

要点

  • 68Ga-PSMA PET/CT检测前列腺癌的灵敏度91.67%、特异度81.82%、PPV 89.19%、NPV 85.71%。
  • 68Ga-PSMA PET/CT的AUC(0.867)高于ERSPC-RC3(0.855)和PCPT-RC(0.770)。
  • SUVmax和前列腺体积是前列腺癌阳性的显著预测因素。

核心结论

  • 在tPSA 0.4-50 ng/ml的疑似前列腺癌患者中,68Ga-PSMA PET/CT在预测癌症和减少不必要的活检方面优于列线图。
  • 前列腺癌风险与更高的SUVmax和更小的前列腺体积正相关。

研究设计与样本

  • 回顾性分析2017年4月至2018年4月在中国一家大型三级医院连续收治的146例疑似前列腺癌患者,最终58例纳入分析。
  • 疑似前列腺癌基于症状或总前列腺特异性抗原(tPSA)水平升高,患者均行68Ga-PSMA PET/CT和组织病理学检查。
  • 由两名经验丰富的核医学专家评估68Ga-PSMA PET/CT结果(前列腺癌或良性)。
  • 使用ERSPC和PCPT列线图评估前列腺癌阳性风险。
  • 通过受试者工作特征(ROC)曲线分析、决策曲线分析和逻辑回归比较诊断效能。

主要发现

  • 58例患者中37例确诊前列腺癌,21例排除前列腺癌。
  • 68Ga-PSMA PET/CT在患者水平分析的灵敏度、特异度、阳性预测值(PPV)和阴性预测值(NPV)分别为91.67%、81.82%、89.19%和85.71%。
  • 68Ga-PSMA PET/CT的AUC(0.867)高于ERSPC-RC3(0.855)和PCPT-RC(0.770)。
  • 68Ga-PSMA PET/CT在阈值概率15-90%的患者中净获益最大。
  • 58例患者中,11例(19%)经ERSPC-RC3建议的活检是不必要的,若根据68Ga-PSMA PET/CT结果判断可避免。

关键数值与推荐

  • 68Ga-PSMA PET/CT患者水平分析:灵敏度91.67%、特异度81.82%、PPV 89.19%、NPV 85.71%、AUC 0.867。
  • ERSPC-RC3的AUC为0.855,PCPT-RC的AUC为0.770。
  • 68Ga-PSMA PET/CT净获益最大的阈值概率范围为15-90%。
  • 58例中11例(19%)经ERSPC-RC3建议的活检可经68Ga-PSMA PET/CT判断避免。

临床怎么用

  • 对于tPSA 0.4-50 ng/ml的疑似前列腺癌患者,可考虑使用68Ga-PSMA PET/CT辅助预测癌症风险。
  • 68Ga-PSMA PET/CT结果有助于减少不必要的活检。
  • SUVmax和前列腺体积可用于初步估计个体癌症风险。
  • 需注意监测68Ga-PSMA PET/CT的假阳性结果。
  • 68Ga-PSMA PET/CT可辅助日常医疗实践中的活检决策。

局限性

  • 本研究为回顾性分析。
  • 最终分析仅纳入58例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the diagnostic performance of 68Ga-PSMA PET/CT for detecting suspected prostate cancer (PCa) and to compare it with that of two cancer-predicting nomograms. METHODS: We performed a retrospective analysis of 146 consecutive patients with suspected PCa based on symptoms or elevated total prostate-specific antigen (tPSA) levels who underwent 68Ga-PSMA PET/CT and histopathologic examinations from April 2017 to April 2018 in a large tertiary care hospital in China. The 68Ga-PSMA PET/CT results (PCa or benignancy) were evaluated by two experienced nuclear medicine specialists. The risk of positive PCa was evaluated using ERSPC and PCPT nomograms. The diagnostic performances of 68Ga-PSMA PET/CT and that of the two nomograms were compared via receiver operating characteristic (ROC) curve analysis, decision curve analysis, and logistic regression. RESULTS: A total of 58 patients with tPSA of 0.4-50 ng/ml were included in the final analysis; PCa diagnosis was confirmed in 37 patients and excluded in 21 patients. ROC analysis showed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 68Ga-PSMA PET/CT were 91.67, 81.82, 89.19, and 85.71%, respectively, in per-patient analyses. 68Ga-PSMA PET/CT exhibited a higher AUC (0.867) than those of ERSPC-RC3 (0.855) and PCPT-RC (0.770). The net benefit of 68Ga-PSMA PET/CT was greatest for patients within threshold probabilities of 15-90%. Among the 58 patients, 11 (19%) biopsies suggested by ERSPC-RC3 were unnecessary and could have been avoided if judged by the 68Ga-PSMA PET/CT results. Multivariate analysis revealed that the maximum standardised uptake value (SUVmax) and prostate volume were significant predictive factors for positive PCa results. CONCLUSION: In suspected PCa patients with tPSA of 0.4-50 ng/ml, 68Ga-PSMA PET/CT outperformed the nomograms in predicting cancer and reducing unnecessary biopsies. In addition, the risk of PCa was positively correlated with a higher SUVmax and lower prostate volume, which could help clinicians in making preliminary estimates of individual cancer risk, monitoring 68Ga-PSMA PET/CT false-positive results and making biopsy decisions in daily medical practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang J, Shao S, Wu P, et al. Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging. 2019. PMID: 30635755. doi:10.1007/s00259-018-4255-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。